Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Declines By 33.0%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 52,800 shares, a decrease of 33.0% from the January 31st total of 78,800 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an average daily volume of 355,200 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Trading of Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC purchased a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned about 0.56% of Alzamend Neuro as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 49.61% of the company’s stock.

Alzamend Neuro Trading Down 7.9 %

Shares of NASDAQ ALZN opened at $0.76 on Tuesday. Alzamend Neuro has a 52-week low of $0.72 and a 52-week high of $15.06. The firm’s fifty day moving average is $1.11 and its two-hundred day moving average is $1.53.

Alzamend Neuro (NASDAQ:ALZN) last issued its earnings results on Wednesday, December 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.38) by $1.98. On average, research analysts forecast that Alzamend Neuro will post -1.68 earnings per share for the current year.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets reduced their price objective on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Monday, December 16th.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.